Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.30 |
| ▸ | FYN | P06241 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1669090 | 0.76 | ALDH1A1 (0.40) | ALDH1A1TDP1FFAR3CES2CES1 | |
| SCHEMBL12758739 | 0.72 | — | — | |
| SCHEMBL5023049 | 0.72 | — | — | |
| SCHEMBL5023053 | 0.72 | — | — | |
| SCHEMBL6253198 | 0.71 | — | — | |
| SCHEMBL12934284 | 0.71 | — | — | |
| SCHEMBL6253196 | 0.71 | — | — | |
| SCHEMBL17685047 | 0.70 | CA4 (0.45) | ALDH1A1FFAR3LCKFYN | |
| SCHEMBL27715000 | 0.70 | — | — | |
| SCHEMBL11162323 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5877210-A | CONTROLLING IMMUNE RESPONSE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-03-02 | — | — | US | claimed |
| US-5583242-A | VANADYL COMPLEXES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-12-10 | — | — | US | claimed |
| US-5565491-A | FOR TREATMENT OF DISEASES MARKED BY MALIGNANT PROLIFERATION OF B CELLS, SUCH AS LEUKEMIA AND LYMPHOMAS; ANTICARCINOGENIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-15 | — | — | US | claimed |
| US-20230241078-A1 | Vanadyl and vanadate for use in reducing stress-induced metabolic derangement | CFM PHARMA HOLDING B.V. (NL) | 2023-08-03 | — | — | US | disclosed |
| US-20200246352-A1 | Vanadyl and vanadate for use in reducing stress-induced metabolic derangement | CFM PHARMA HOLDING B.V. (NL) | 2020-08-06 | — | — | US | disclosed |
| EP-3684352-A1 | VANADYL AND VANADATE FOR USE IN REDUCING STRESS -INDUCED METABOLIC DERANGEMENT | CFM Pharma Holding BV (NL) | 2020-07-29 | — | — | EP | disclosed |
| WO-2019059770-A1 | VANADYL AND VANADATE FOR USE IN REDUCING STRESS -INDUCED METABOLIC DERANGEMENT | CFM PHARMA HOLDING B.V. (NL) | 2019-03-28 | — | — | WO | disclosed |
| US-5877210-A | CONTROLLING IMMUNE RESPONSE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-03-02 | — | — | US | disclosed |
| US-5846998-A | Use of phosphotyrosine phosphatase inhibitors or phosphotyrosine kinase activators for controlling cellular proliferation | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-12-08 | — | — | US | disclosed |
| US-5693627-A | TREATING DISEASES SUCH AS LEUKEMIAS AND LYMPHOMAS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-12-02 | — | — | US | disclosed |
| US-5583242-A | VANADYL COMPLEXES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-12-10 | — | — | US | disclosed |
| US-5565491-A | FOR TREATMENT OF DISEASES MARKED BY MALIGNANT PROLIFERATION OF B CELLS, SUCH AS LEUKEMIA AND LYMPHOMAS; ANTICARCINOGENIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-15 | — | — | US | disclosed |
| EP-0735880-A1 | USE OF VANADIUM MOLYBDENUM OR TUNGSTEN COMPLEXES FOR CONTROLLING CELLULAR PROLIFERATION | Bristol-Myers Squibb Company (US) | 1996-10-09 | — | — | EP | disclosed |
| WO-1995020390-A1 | USE OF VANADIUM MOLYBDENUM OR TUNGSTEN COMPLEXES FOR CONTROLLING CELLULAR PROLIFERATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-08-03 | — | — | WO | disclosed |